Dr June Ren, chief executive of the British Vaccine Regulatory Agency (MHRA), said the MHRA experts had approved a vaccine from France’s Valneva. For the prevention of COVID-19 states that it meets all the requirements of the MHRA in terms of safety. Quality and effectiveness of prevention of COVID-19 It is the first inactivated vaccine to be approved for use in the UK. It is the sixth vaccine the UK has approved to protect against COVID-19. And is the first country in the world to approve this vaccine.
The MHRA recommends the use of the Val Neva vaccine. For patients aged 18-50 years, it is a two-dose vaccine, with the second dose being administered 28 days away from the first dose. Another advantage of the Val Neva vaccine is that the vaccine can be stored in a common household refrigerator with temperature. Average 2-8 degrees Celsius, making it suitable for many countries where it may not be convenient to store vaccines at lower temperatures.
It also uses a manufacturing method commonly used to produce flu and polio vaccines. Then use the disinfection process to kill the virus. Prevents the virus from infecting other cells or multiplying in the body. At the same time, it can also stimulate the immune system in the body to prevent the spread of COVID-19.
Valneva expects the European Medicines Agency, as the European regulatory body for vaccines, to consider approving the Vulnera vaccine for the prevention of COVID-19. The European Union (EU) also this month said it was 87 percent effective against both earlier strains of viruses such as Delta and Omicron.
Late last year, Dr. Chalermchai Boonyaleephan (Dr. Chalermchai), Vice-President of the Senate Public Health Commission, posted information on an inactivated vaccine invented by France. It is Europe’s first deadly coronavirus vaccine, France’s Valneva said in a statement that it has been researching and developing a lethal vaccine since January 2020, but has encountered some obstacles, so it only progressed to a phase 3 trial last year. Then and now there is England. Interested in pre-ordering 100 million doses
The French company Valneva has developed a vaccine, called VLA 2001, that uses a whole-body virus to kill it, known as a lethal vaccine. It will focus on having the main protein (S-protein), but there will also be other parts. It is expected to support the mutant virus well. because there are different parts of the virus Not only the thorns The vaccine is administered with two adjuvants, alum and CpG 1018, which raise the immune system. It is expected that the vaccine It is suitable for injection in high-risk groups such as old age or low immunity. And it is expected to be very useful as a booster vaccine after other technology vaccines.
Phase three trials were conducted in England and New Zealand.
#England
#French vaccine approved